Cargando…

Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer.

Increased understanding of the molecular basis of colorectal cancer and recognition that extracellular DNA circulates in the plasma and serum of cancer patients enables new approaches to detection and monitoring. We used a polymerase chain reaction (PCR) assay to demonstrate mutant K-ras DNA in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kopreski, M. S., Benko, F. A., Kwee, C., Leitzel, K. E., Eskander, E., Lipton, A., Gocke, C. D.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1997
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228153/ https://www.ncbi.nlm.nih.gov/pubmed/9374374

Ejemplares similares

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
por: Fernández Montes, A., et al.
Publicado: (2022)

Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
por: Raimondi, Cristina, et al.
Publicado: (2019)

Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer
por: Bouchahda, Mohamed, et al.
Publicado: (2020)

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2019)

Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation
por: Ferguson, Robert, et al.
Publicado: (2023)

Detection of Mutant RAS Subpopulations in Colorectal Cancer Patients
por: Banda, Malathi
Publicado: (2015)

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients
por: Vidal, J, et al.
Publicado: (2017)

Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
por: Jin, Hua, et al.
Publicado: (2019)

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2023)

Comparative Analysis of Radiosensitizers for K-RAS Mutant Rectal Cancers
por: Kleiman, Laura B., et al.
Publicado: (2013)

5-Arylidene(chromenyl-methylene)-thiazolidinediones: Potential New Agents against Mutant Oncoproteins K-Ras, N-Ras and B-Raf in Colorectal Cancer and Melanoma
por: Nastasă, Cristina, et al.
Publicado: (2019)

Fast simultaneous detection of K-RAS mutations in colorectal cancer
por: Chang, Ya-Sian, et al.
Publicado: (2009)

Spectrum of K ras mutations in Pakistani colorectal cancer patients
por: Murtaza, B.N., et al.
Publicado: (2013)

Blocking K-Ras Interaction With the Plasma Membrane Is a Tractable Therapeutic Approach to Inhibit Oncogenic K-Ras Activity
por: Henkels, Karen M., et al.
Publicado: (2021)

Decreased GTPase activity of K- ras mutants deriving from human functional adrenocortical tumours
por: Lin, S-R, et al.
Publicado: (2000)

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib
por: Booth, Laurence, et al.
Publicado: (2017)

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening
por: Verissimo, Carla S, et al.
Publicado: (2016)

Comparison of K-ras mutations in lung, colorectal and gastric cancer
por: PENG, NANQIU, et al.
Publicado: (2014)

Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer Through GTPase Signaling Pathways
por: Padavano, Julianna, et al.
Publicado: (2015)

Therapeutic impact of determination of RAS mutations in the plasma of patient with colorectal cancer
por: Macedo, F, et al.
Publicado: (2022)

Temporal Dissection of K-ras(G12D) Mutant In Vitro and In Vivo Using a Regulatable K-ras(G12D) Mouse Allele
por: Wang, Zuoyun, et al.
Publicado: (2012)

The Importance of Mg(2+)‐Free State in Nucleotide Exchange of Oncogenic K‐Ras Mutants
por: Pálfy, Gyula, et al.
Publicado: (2022)

Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11)
por: Sunakawa, Y., et al.
Publicado: (2022)

Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan
por: Ikoma, Tatsuki, et al.
Publicado: (2021)

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6
por: Sorokin, Alexey V., et al.
Publicado: (2022)

Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma
por: Thomsen, C. B., et al.
Publicado: (2018)

Mutant K-ras oncogene regulates steroidogenesis of normal human adrenocortical cells by the RAF-MEK-MAPK pathway
por: Wu, C-H, et al.
Publicado: (2002)

Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer
por: Caetano, Mauricio S., et al.
Publicado: (2018)

The detection of K-ras mutations in colorectal cancer using the amplification-refractory mutation system.
por: Fox, J. C., et al.
Publicado: (1998)

Differences in K-ras and mitochondrial DNA mutations and microsatellite instability between colorectal cancers of Vietnamese and Japanese patients
por: Miwata, Tomohiro, et al.
Publicado: (2014)

Involvement of APC and K-ras mutation in non-polypoid colorectal tumorigenesis
por: Umetani, N, et al.
Publicado: (2000)

Correction: Temporal Dissection of K-ras(G12D) Mutant In Vitro and In Vivo Using a Regulatable K-ras(G12D) Mouse Allele
por: Wang, Zuoyun, et al.
Publicado: (2012)

Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients
por: Nicolazzo, Chiara, et al.
Publicado: (2020)

Analysis of Efficacy, Safety, and Prognostic Factors of mFOLFOX6 Regimen Combined with Cetuximab and Simvastatin in the Treatment of K-RAS Mutant Colorectal Cancer
por: Li, Guodong, et al.
Publicado: (2021)

Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line
por: Tokunaga, T, et al.
Publicado: (2000)

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
por: Yuan, Xi, et al.
Publicado: (2020)

Vav1 and mutant K-Ras synergize in the early development of pancreatic ductal adenocarcinoma in mice
por: Salaymeh, Yaser, et al.
Publicado: (2020)

Nrf2 Activation Sensitizes K-Ras Mutant Pancreatic Cancer Cells to Glutaminase Inhibition
por: Hamada, Shin, et al.
Publicado: (2021)

Targeting IL-1β as an immunopreventive and therapeutic modality for K-ras–mutant lung cancer
por: Yuan, Bo, et al.
Publicado: (2022)

Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
por: Cekani, Elona, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jh6rpj4bbfdr5kj00cemk5gst9